Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Mabpharm Limited ( (HK:2181) ) just unveiled an announcement.
Mabpharm Limited has announced changes to its board and committee structure effective October 31, 2025. Dr. Qian Weizhu has joined the Nomination Committee, while Mr. Tao Jing has stepped down from it. Dr. Zhang Yanyun has been appointed as the lead independent non-executive director, tasked with enhancing communication within the board and with shareholders. These changes align with recent amendments to the Hong Kong Stock Exchange’s Listing Rules and aim to improve the board’s effectiveness and diversity, thereby strengthening corporate governance practices.
The most recent analyst rating on (HK:2181) stock is a Hold with a HK$0.50 price target. To see the full list of analyst forecasts on Mabpharm Limited stock, see the HK:2181 Stock Forecast page.
More about Mabpharm Limited
Average Trading Volume: 701,064
Technical Sentiment Signal: Buy
Current Market Cap: HK$2.35B
See more data about 2181 stock on TipRanks’ Stock Analysis page.